Sistema EVOQUE: reemplazo tricuspídeo transcatéter, resultados al año

TAVR: High Implantation of Self-Expanding Valves Directly Impacts ECG

TAVR has been shown beneficial, especially in high risk or inoperable patients. However, there are limitations to its use, especially with self-expanding valves, which are the need for pacemaker implantation and ECG changes after procedure.  To address this matter, researchers assessed the right and left cusp overlap effect on 254 patients undergoing TAVR with self-expanding<a href="https://solaci.org/en/2024/01/11/tavr-high-implantation-of-self-expanding-valves-directly-impacts-ecg/" title="Read more" >...</a>

Interventional Cardiology: The Most Read Articles of 2023

Discover the most read scientific articles on interventional cardiology of 2022 in our website. No Reflow after Primary PCI in STEMI: An Angiographic Analysis of the TOTAL Study In the early days of percutaneous coronary intervention (PCI) in patients with ST elevation acute myocardial infarction (STEMI), no reflow phenomenon was known as an indicator of<a href="https://solaci.org/en/2023/12/27/interventional-cardiology-the-most-read-articles-of-2023/" title="Read more" >...</a>

Luz roja para el TAVI en pacientes de bajo riesgo

MYVAL, a TAVR Balloon-Expandable Valve with Promising Results

TAVR has been shown beneficial over time, and with the development of new generation of prosthetic valves and implantation techniques, outcomes have been improved, reducing the incidence of leaks y and the need for definite pacemaker.  This study looked at the evolution of 100 patients with symptomatic aortic stenosis treated with Myval THV from Meril<a href="https://solaci.org/en/2023/12/19/myval-a-tavr-balloon-expandable-valve-with-promising-results/" title="Read more" >...</a>

EVOQUE: Transcatheter Tricuspid Valve Replacement, One-Year Outcomes

Treating tricuspid regurgitation (TR) has gained increasing importance in interventionism. There is abundant literature on the negative natural evolution of this condition and its unfavorable prognosis, as well as the clinical challenges associated to optimal medical treatment.  Among its percutaneous treatment options, both edge-to-edge repair devices (TEER), as showed in TriValve and TRILUMINATE trials, and<a href="https://solaci.org/en/2023/12/15/evoque-transcatheter-tricuspid-valve-replacement-one-year-outcomes/" title="Read more" >...</a>

New Advances in Mitral Regurgitation Devices with Promising Results

Mitral regurgitation (MR) is a frequent valvulopathy and when the optimal medical treatment at maximum tolerated doses is not enough, surgery is the first course of action. And even though edge-to-edge repair with clips has seen substantial improvement, it is currently reserved for those at high risk of surgery.  However, there is an increasing number<a href="https://solaci.org/en/2023/12/15/new-advances-in-mitral-regurgitation-devices-with-promising-results/" title="Read more" >...</a>

SAFE-TAVI Study: Safety and Efficacy of the Pressure Sensor and Pacing Guidewire

Currently, we observe an increase in the number of transcatheter aortic valve replacement (TAVR) procedures due to its expansion toward a younger population with lower risk. For this reason, it is crucial to maintain continuous technological innovation to minimize post-procedural complications. The FDA has approved the SavyWire, a preformed 0.035-caliber guidewire that offers three essential<a href="https://solaci.org/en/2023/12/14/safe-tavi-study-safety-and-efficacy-of-the-pressure-sensor-and-pacing-guidewire/" title="Read more" >...</a>

Debemos tener en cuenta a la isquemia crítica de MM II en el TAVI

Low Gradient, Normal Flow Aortic Stenosis: Changes in Quality of Life with TAVR

There is no question as regards the recommended treatment for symptomatic severe aortic stenosis, seeing as both transcatheter and surgical aortic valve replacement (TAVR and SAVR) have shown to significantly improve prognosis. This is despite the fact that there is still certain ambiguity around its characterization, which looks to define it according to hemodynamic severity<a href="https://solaci.org/en/2023/11/30/low-gradient-normal-flow-aortic-stenosis-changes-in-quality-of-life-with-tavr/" title="Read more" >...</a>

AHA 2023 | Use of Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Subclinical atrial fibrillation (AF), generally asymptomatic and of short duration, often requires continuous long-term monitoring using pacemakers or defibrillators for its detection. While subclinical AF is linked to an increased risk of stroke, the usefulness of oral anticoagulation as a treatment remains uncertain. In a double-blind randomized trial, one group received apixaban and the other<a href="https://solaci.org/en/2023/11/14/aha-2023-use-of-apixaban-for-stroke-prevention-in-subclinical-atrial-fibrillation/" title="Read more" >...</a>

See the Presentations of the 13th ProEducar Fellows Course

  During SOLACI-SBHCI 2023, our traditional education program for young interventionists ProEducar Fellows Course was held.  Discover the presentations of the prestigious interventionists that made part of this 13th edition here below.  Dr. Gustavo Vignolo (UY) – “Trigger: STEMI learning clinical case” PRESENTATION Dr. Roger Renault Godinho (BRA) – “Why and how should I use Radial access? Step by Step” PRESENTATION<a href="https://solaci.org/en/2023/11/10/see-the-presentations-of-the-13th-proeducar-fellows-course/" title="Read more" >...</a>

Is TAVR Beneficial in Cardiogenic Shock?

The presence of cardiogenic shock (CS) in a setting of aortic stenosis ranges from 1% to 4%. The prognosis for this scenario is ominous due to subendocardial ischemia, which presents as a decrease in ventricular preload and an increase in afterload. Aortic valvuloplasty has been used in this context, but, unfortunately, it has been associated<a href="https://solaci.org/en/2023/11/09/is-tavr-beneficial-in-cardiogenic-shock/" title="Read more" >...</a>